Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Is First Splash In HIV Patent Pool; Five Other Firms In Negotiations

This article was originally published in The Pink Sheet Daily

Executive Summary

Gilead's deal with the Medicines Patent Pool limits the developing countries that have access to generics and requires that the drugs be manufactured in India.
Advertisement

Related Content

Deals Of The Week Untangles The String Of Pearls
AIDS Patent Pool Garners Support From Industry, But Pharma Companies Want Flexibility In Pricing Between Countries
AIDS Patent Pool Garners Support From Industry, But Pharma Companies Want Flexibility In Pricing Between Countries

Topics

Advertisement
UsernamePublicRestriction

Register

PS072503

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel